Gene · 134
Papers2,244
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,244
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Specific GPCRs elicit unique extracellular vesicle miRNA array signatures. | Elife | 2026 | 41860956 | PubTator, text mining | PubMed |
| Monocytes from inflammatory arthritis patients accumulate methotrexate and their transcriptome predicts methotrexate clinical response. | Cell Mol Life Sci | 2026 | 41840229 | PubTator, text mining | PubMed |
| Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer. | J Immunother Cancer | 2026 | 41825935 | PubTator, text mining | PubMed |
| Habitual coffee consumption poorly correlates with sleep quality and daytime sleepiness: A cross-sectional study. | PLoS One | 2026 | 41801928 | PubTator, text mining | PubMed |
| Latest surface plasmon resonance advances for G protein-coupled receptors. | J Pharm Anal | 2026 | 41767747 | PubTator, text mining | PubMed |
| Association Between Caffeine Levels and Symptom Profile in Schizophrenia: Results from a Cohort Study in Central Greece. | Brain Sci | 2026 | 41750209 | PubTator, text mining | PubMed |
| Identifying Metabolite-Disease Associations via Messaging in Hypergraphs. | Metabolites | 2026 | 41745599 | PubTator, text mining | PubMed |
| Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies. | Diseases | 2026 | 41745121 | PubTator, text mining | PubMed |
| RNA cargo profiling of muscle extracellular vesicles identifies candidate biomarkers of disease activity and muscle degeneration in FSHD. | J Transl Med | 2026 | 41742280 | PubTator, text mining | PubMed |
| The Intersection of m6A Methylation and Immune Response in PCOS: A Bioinformatics Perspective. | Immun Inflamm Dis | 2026 | 41725222 | PubTator, text mining | PubMed |
| Mechanistic insights and therapeutic interventions of mitochondrial quality control in chemotherapy-related cognitive impairment. | Neoplasia | 2026 | 41723889 | PubTator, text mining | PubMed |
| Prioritization of novel druggable targets for epilepsy via Mendelian randomization and colocalization. | Behav Brain Res | 2026 | 41698610 | PubTator, text mining | PubMed |
| Protein structural dynamics in covalent drug design: insights from irreversible and reversible covalent inhibitors. | RSC Chem Biol | 2026 | 41623523 | PubTator, text mining | PubMed |
| Neuroimmune circuits in respiratory pathophysiology: decoding molecular crosstalk for precision therapeutic targeting. | Ann Med | 2026 | 41601146 | PubTator, text mining | PubMed |
| CD73 restrains mutant β-catenin oncogenic activity in endometrial carcinomas. | JCI Insight | 2026 | 41574604 | PubTator, text mining | PubMed |
| Repeated adenosine A1 receptor antagonism rewires ventral hippocampus-ventral tegmental area transmission and enhances stress-coping responses. | Prog Neuropsychopharmacol Biol Psychiatry | 2026 | 41544882 | PubTator, text mining | PubMed |
| Inhibition of Retinal AdoRA2a Activity Attenuates Myopia Progression. | Invest Ophthalmol Vis Sci | 2026 | 41533917 | PubTator, text mining | PubMed |
| Two-Step Ligand-Directed Covalent Fluorescent Labeling of the Adenosine A1-Receptor That Maintains Its Orthosteric Binding Site's Availability to Bind Ligands. | J Med Chem | 2026 | 41506868 | PubTator, text mining | PubMed |
| Evaluating the adenosine hypothesis of restless legs syndrome and its implications for current and future treatment strategies. | Expert Rev Neurother | 2026 | 41388724 | PubTator, text mining | PubMed |
| Precision Targeting in Gastric Cancer: AI-Driven Discovery of MET, ADORA2A, CDK5R1, and ADORA1. | Assay Drug Dev Technol | 2026 | 40932634 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/134/papers?page=2